Magnesium L-ThreonatevsSulbutiamine

The L-threonate carrier forms stable complexes with magnesium and transports it across the blood-brain barrier via specific transporters more effectively than inorganic magnesium salts or other chelated forms. Once in the brain, magnesium acts as a voltage-dependent blocker of the NMDA receptor channel at the physiological magnesium binding site within the ion pore, preventing excessive calcium influx and glutamate-mediated excitotoxicity. Magnesium also serves as a cofactor for over 300 enzymes including those involved in neurotransmitter synthesis (tyrosine hydroxylase, glutamic acid decarboxylase), ATP production (creatine kinase, pyruvate kinase), and DNA/RNA polymerase. Elevated brain magnesium enhances synaptic density and plasticity in the hippocampus and prefrontal cortex, likely through CREB-mediated gene expression and increased density of postsynaptic AMPA receptors.

Sulbutiamine consists of two thiamine (vitamin B1) molecules connected by a disulfide bridge, conferring lipophilicity and efficient blood-brain barrier penetration via passive diffusion. In the brain, it is hydrolyzed to thiamine and increases thiamine diphosphate (TDP) levels—the cofactor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase, enzymes critical for glucose metabolism and the Krebs cycle. Sulbutiamine upregulates D1 dopamine receptors in the prefrontal cortex, possibly through reduced receptor internalization or increased expression. It modulates glutamatergic transmission (affecting NMDA/AMPA receptor function) and enhances cholinergic transmission. The anti-fatigue and memory-enhancing effects likely stem from improved neuronal glucose oxidation, increased ATP production, and enhanced dopaminergic and cholinergic tone in cognitive circuits.